Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cell-mediated Immune Responses

Cell-mediated Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy.

Cell·2026

Same author

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

The New England journal of medicine·2026

Same author

Bioinspired oxidized mRNA lipid nanoparticles for ex vivo engineering of chimeric antigen receptor macrophages targeting solid tumors.

Bioengineering & translational medicine·2026

Same author

A generalizable system for antigenic peptide targeting across HLA-I allotypes.

bioRxiv : the preprint server for biology·2026

Same author

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy.

The New England journal of medicine·2026

Same author

HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering.

Nano letters·2026

Same journal

Resolution Biology in Soft Tissue Joint Disease.

Current topics in microbiology and immunology·2026

Same journal

A 25+ Year Journey on Yeast-Regulated Cell Death Research.

Current topics in microbiology and immunology·2026

Same journal

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026

Same journal

Resolution Pharmacology Targeting the Melanocortin System.

Current topics in microbiology and immunology·2026

Same journal

Resolution of Skeletal Muscle Inflammation: Role of Specialized Pro-resolving Lipid Mediators in the Recovery from Exercise, Injury, and Disease.

Current topics in microbiology and immunology·2026

Same journal

Epstein-Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Strains.

Current topics in microbiology and immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Adoptive cellular therapy.

Stephan A Grupp¹, Carl H June

¹Division of Oncology and Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Current Topics in Microbiology and Immunology

|August 12, 2010

Summary

This summary is machine-generated.

Adoptive cell therapy (ACT) shows promise for cancer immunotherapy, especially after hematopoietic stem cell transplantation (HSCT). Genetically engineered lymphocytes can enhance anti-tumor immunity and improve treatment outcomes.

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Related Experiment Videos

Last Updated: Jun 10, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Cancer immunotherapy utilizes cell-based strategies involving lymphocytes and antigen-presenting cells.
Adoptive cell therapy (ACT), specifically T lymphocyte transfusion, is effective for viral infections and shows cancer regression potential.
Immune reconstitution post-hematopoietic stem cell transplantation (HSCT) is often impaired, increasing infection and relapse risks.

Purpose of the Study:

To explore the applications of ACT in cancer immunotherapy.
To discuss advancements and challenges in clinical translation of ACT.
To highlight ACT's role in enhancing immunity post-HSCT.

Main Methods:

Review of current research on adoptive cell therapy (ACT).
Focus on T lymphocyte transfusion and genetically engineered lymphocytes.
Analysis of ACT's efficacy in preclinical and clinical settings, particularly post-HSCT.

Main Results:

ACT has demonstrated efficacy in treating viral infections and inducing cancer regression.
Genetically engineered lymphocytes can improve immune responses and redirect T cells against tumors.
ACT holds potential to augment antitumor immunity and vaccine efficacy after HSCT.

Conclusions:

Adoptive cell therapy (ACT) is a promising modality for cancer immunotherapy, especially in the post-HSCT setting.
Genetic engineering of lymphocytes offers enhanced therapeutic potential for cancer treatment.
Further research is needed to overcome hurdles in translating ACT technologies to clinical practice.